The organ transplantation system is viewed as one of our most equitable health care services, but poor patients are effectively excluded by policy that denies Medicaid coverage of post-transplant immunosuppressant medication.
The proliferation of enhancement technologies and pharmacological agents has perpetuated the view of American doctors and patients of medical care as a market commodity driven by what consumers want and are willing to pay for.
A bioethicist argues that children with Down syndrome should not be subjected to cosmetic surgery to change their appearance unless they are at the age and have the capacity to make the decision for themselves.
This article asks whether the benefits of neuroelectronic devices that restore function outweigh their risks to the individual and society and whether we should move beyond therapy to enhance our capabilities by the use of such devices?
US attitudes toward aging drive patient demands for elective medical and surgical services. Ethical physicians must make sure patients have realistic expectations.